Good Outcomes Seen With Hyperfractionated Conformal RT

Oncology NEWS InternationalOncology NEWS International Vol 6 No 1
Volume 6
Issue 1

LOS ANGELES--By using hyper-fractionation, radiation oncologists at Wayne State University were able to deliver an isocenter dose of 85 Gy to the prostate in men with locally advanced prostate cancer, producing a 95% negative biopsy rate.

LOS ANGELES--By using hyper-fractionation, radiation oncologists atWayne State University were able to deliver an isocenter dose of 85 Gyto the prostate in men with locally advanced prostate cancer, producinga 95% negative biopsy rate.

"Instead of giving a standard fraction of 1.8 to 2.0 Gy once aday up to a standard total dose of about 70 Gy, we gave 1.15 Gy twice aday," said Jeffrey D. Forman, MD, in an interview about his posterpresentation at the American Society for Therapeutic Radiology and Oncology(ASTRO) (see illustration).

Using conformal radiation and 3D treatment planning in prostate cancerpatients, researchers have been able to reduce the amount of radiationto the surrounding normal tissue, but were still encountering significantcomplications at high doses. "Careful and precise aiming by itselfwas not sufficient to prevent complications to the rectum and bladder,"Dr. Forman said, "so we turned to hyperfractionation, ie, the deliveryof multiple, smaller than normal fractions of radiation each day."

No Severe Complications

Hyperfractionation is effective at treating cancer while sparing normaltissue, he said, because the effect of treatment on the cancer is dictatedby the maximum total radiation dose, while the effect on normal cells dependsmore on the size of each individual dose.

In Dr. Forman's dose-escalation study using hyperfractionated conformalradiotherapy, there were no severe complications at the first dose levelof 80 Gy, and about half the patients had negative findings on post-radiationbiopsies, "an improvement over the 25% negative biopsy rate generallyseen with standard doses," he said.

These patients were monitored for about a year before the researchersmoved to the next dose level of 85 Gy. Again, there were no severe complicationsamong the 24 patients receiving this dose level, and the negative biopsyrate rose to 95%.

This created a dilemma, Dr. Forman pointed out. Although the low toxicityjustified continuing the study to the next dose level of 90 Gy, "because95% of patients had no cancer in their biopsy specimen, we felt that ethically,it didn't make sense to continue to the next dose level, since it wouldbe hard to improve on those results."

The researchers elected to close the study early and continue to monitorthe patients who received the 85 Gy dose to make sure that local controlrates are maintained. "If they are not maintained, then we will goto the next dose level; if they are, then we're done," Dr. Formansaid, adding that the next goal would be to confirm the results in a largerclinical trial. Currently, he said, the patients have been followed for2 to 4½ years.

In this protocol, the fractions were given at 6- to 8-hour intervals,so patients could come in at 7 or 8 AM for their first treatment and returnabout 4 PM for their second dose, he said, allowing patients who were workingto work a full day between treatments. The treatment, which continued for7½ weeks, was well tolerated, with patients able to maintain theirnormal daily activities.

Somewhat confounding the results was the fact that many patients alsoreceived preradiation hormonal therapy. "Between the time in early1992 when we opened the study and treated patients at the first dose leveland the time we started the second dose level, data on RTOG 8610 becameavailable showing that in this population of patients, preradiation hormonaltherapy is beneficial, so we elected to include that in the treatment regimen,"he said. All but four patients at the second dose level received pretreatmenthormones.

Dr. Forman acknowledged that the hormonal treatment contributed to theexcellent results seen at the 85 Gy dose level. "Some people criticizedthe study, saying that by adding hormonal therapy, we were losing the abilityto know how much was really gained from the increased dose, but from myperspective, the goal of the treatment is to get rid of the cancer withoutserious side effects, and if it takes two types of treatment to do that,I'm not really concerned with knowing the precise contribution of eachtreatment."

Dr. Forman's colleagues in the study were Arthur T. Porter, MD, PaulKocheril, MD, David Grignon, MD, and Colin Orton, PhD.

Related Videos
Robust genetic testing guidelines in the prostate cancer space must be supported by strong clinical research before they can be properly implemented, says William J. Catalona, MD.
Financial constraints and a lack of education among some patients and providers must be addressed to improve the real-world use of certain prostate cancer therapies, says Neeraj Agarwal, MD.
Novel anti-PSMA monoclonal antibody rosopatamab is capable of carrying a bigger payload of radiation particles, which may potentially reduce doses for patients with prostate cancer, says Neeraj Agarwal, MD.
Findings from recent studies support the use of artificial intelligence-based tools in the context of radiation therapy for patients with localized prostate cancer, according to Neeraj Agarwal, MD.
Germline testing may elucidate important mutations in patients with metastatic prostate cancer who may be eligible to receive treatment with PARP inhibitors, according to Neeraj Agarwal, MD.
In this September edition of Snap Recap, we share our highlights from Prostate Cancer Awareness Month, news in the breast cancer space, and the latest FDA updates.
Artificial intelligence programs may help introduce new care strategies that minimize the risk of adverse effects in patients with prostate cancer, according to Wayne G. Brisbane, MD.
An artificial intelligence algorithm appears to create accurate focal treatment margins in patients with prostate cancer, according to Wayne G. Brisbane, MD.
Artificial intelligence may be useful in screening for prostate cancer in patients with elevated prostate specific antigen levels who have undergone MRI, according to Wayne G. Brisbane, MD.
Alicia K. Morgans, MD, MPH, from Dana-Farber Cancer Institute indicates that patients with non-metastatic castration-resistant prostate cancer are able to stay on treatment for long periods of time with darolutamide vs enzalutamide and apalutamide.
Related Content